Le Lézard
Classified in: Health, Business
Subject: CON

Unifeye Vision Partners Completes Partnership with Southern California Desert Retina Consultants


DALLAS, Oct. 7, 2021 /PRNewswire/ -- Unifeye Vision Partners ("UVP" or "the Company"), a leading network of comprehensive eye care providers, today announced the completion of a new strategic partnership with Palm Desert-based Southern California Desert Retina Consultants ("Desert Retina").  Desert Retina serves patients in the Palm Springs, Palm Desert, and Inland Empire.  The partnership expands upon UVP's existing presence within the Inland Empire region, including both Upland-based Pacific Eye Institute and Rancho Cucamonga-based Inland Eye Institute.

Unifeye Vision Partners expands into Palm Springs and Palm Desert

Well-respected in the field of ophthalmology, the team at Desert Retina specializes in the treatment of diseases of the retina, vitreous, and macula, including retina detachments.  Trained in the latest treatment and surgical techniques, their physicians Clement K. Chan, M.D., and Steven G. Lin, M.D., regularly participate in research and clinical trials which have been featured in numerous medical journals.  Together with their clinic teams, the practice serves patients in Palm Springs, Palm Desert, and Riverside, California.    

"We are excited to finalize our partnership with UVP," said Dr. Clement Chan, founder and Managing Partner of Desert Retina.  "We were drawn to UVP because they prioritize people-centric values and place physicians, our team members and exceptional patient care at the heart of all practice management decisions.  We look forward to working and growing with UVP."  

"We're excited to welcome Desert Retina to the UVP community," said Sami Abbasi, President and CEO of Unifeye Vision Partners.   "Dr. Chan and his team bring more than 32 years of retinal experience serving the greater Coachella Valley and Inland Empire markets and have earned an outstanding reputation for delivering clinical excellence and compassionate patient care.  Their expertise allows us to extend our retinal subspecialty offerings to the referring physician and patient communities that we serve.  We look forward to supporting their team and furthering their growth throughout the region."

UVP was formed in 2017 with a growth investment from private equity firm Waud Capital Partners.  This partnership represents the continued execution of the Company's strategy of partnering with leading eye care providers and supporting their growth.

About Unifeye Vision Partners

Unifeye Vision Partners was formed to partner with leading eye care providers in targeted markets throughout the United States. The company provides management and support services to ophthalmology and optometry practices, as well as single-specialty eye surgery centers.   UVP extends its operations to a network of 91 providers, 32 clinical locations, and 6 ambulatory surgery centers. 

For additional information on UVP, visit the Company's website at www.uvpeye.com.

About Waud Capital Partners

Waud Capital Partners is a leading growth-oriented private equity firm with total capital commitments of approximately $3.2 billion since its founding in 1993. The firm partners with exceptional management teams to build market-leading companies within two industries: healthcare services and business and technology services. Since its founding, Waud Capital has successfully completed more than 325 investments, including platform companies and follow-on opportunities. 

For additional information on Waud Capital, visit the firm's website at www.waudcapital.com.

SOURCE Unifeye Vision Partners Management, LLC


These press releases may also interest you

at 02:05
AstraZeneca: Revenue and EPS summary     Q1 2024 % Change $m Actual CER1 - Product Sales 12,177 15 18 - Alliance Revenue   457 59 59...

at 02:00
Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending March 31, 2024. The earnings release, investor presentation and webcast are available at www.indivior.com. The earnings release can be found at...

at 02:00
In response to the increasing complexities of the aging journey and the rising trend of...

at 02:00
PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that it has entered into a target-exclusive research and...

at 02:00
Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood...

at 01:24
Sedana Medical AB (publ) announces that all 235 randomized patients have been recruited for its INSPiRE-ICU 1 phase III clinical trial in the United States. Concurrently, the identical INSPiRE-ICU 2 trial is nearing completion, with 23 of 235...



News published on and distributed by: